Advertisement
Advertisement
U.S. markets close in 6 hours 30 minutes
Advertisement
Advertisement
Advertisement
Advertisement

West Pharmaceutical Services, Inc. (WST)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
256.76-4.39 (-1.68%)
As of 09:30AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close261.15
Open259.44
Bid0.00 x 800
Ask261.75 x 1200
Day's Range256.76 - 256.76
52 Week Range244.71 - 475.00
Volume4,085
Avg. Volume397,235
Market Cap19.013B
Beta (5Y Monthly)1.18
PE Ratio (TTM)28.62
EPS (TTM)8.97
Earnings DateOct 26, 2022 - Oct 31, 2022
Forward Dividend & Yield0.72 (0.28%)
Ex-Dividend DateJul 19, 2022
1y Target Est383.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-15% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for WST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • West Pharmaceutical Services, I
    Analyst Report: West Pharmaceutical Services, Inc.West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (82% of 2021 sales) and contract-manufactured products (18%). It generates 55% of its revenue from international markets and 45% from the United States.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
Advertisement
Advertisement